Anti-tumor necrosis factor (TNF) therapy in pregnant women with inflammatory bowel disease (IBD) can be discontinued before week 30 of gestation without increasing relapse risk or harming the fetus, researchers report.
Reuters Health Information
Anti-tumor necrosis factor (TNF) therapy in pregnant women with inflammatory bowel disease (IBD) can be discontinued before week 30 of gestation without increasing relapse risk or harming the fetus, researchers report.
Reuters Health Information
